Default company panoramic image

GlySure Ltd

Best in class continuous glucose monitor enables hospital ICU clinicians to safely implement Intensive Insulin Therapy, a $1.5B opportunity.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Abingdon, England, GB
  • Currency USD
  • Founded May 2006
  • Employees 23
  • Website

Company Summary

In 2001 Greet Van den Berghe demonstrated that tightly controlling ICU glucose levels resulted in significant improvements in outcomes including 34% reduction in mortality and 46% reduction in incidence of sepsis while also reducing the cost of care. The combination of existing outcomes data with the lack of a Simple, Accurate, Fast, and Easy (S.A.F.E.) way to monitor glucose levels in intensive care has created a $1.5B market opportunity.


  • Default avatar
    Chris Jones

    Mr. Jones has over 20 years of experience in the medical device and diagnostic industry. Prior to joining GlySure in 2008 he was CEO of Tensys Medical and led the development of the first clinically acceptable, cNiBP monitor. He spent nine years with Nellcor Inc, a division of Tyco, most recently as VP of Marketing responsible for the pulse oximetry and critical care businesses, and has a B.S. in Molecular Biophysics and Biochemistry from Yale.

  • Default avatar
    Barry Crane

    Mr. Crane has more than 25 years of experience in the medical device industry. He directed the trans-Atlantic teams of scientists and engineers that were responsible for the development and launch, in 1995, of the first intravascular optical blood gas sensor at Pfizer. Prior to Biomedical Sensors, Mr. Crane worked for Smith & Nephew and Pfizer. Mr. Crane is one of the co-founders of GlySure Ltd and holds degrees in Chemistry and Microbiology.

  • Default avatar
    John Bradshaw

    Mr. Bradshaw is a Chartered Accountant with more than ten years' experience as a CFO with venture capital backed and listed companies. Following 11 years with Arthur Andersen in Cambridge and Turin, he joined Gyrus Group PLC as CFO prior to listing it on the London Stock Exchange. More recently he has been the CFO at Plastic Logic, Analysys Ltd, and TeraView Ltd. Mr. Bradshaw has a degree in Law from the University of Liverpool.

  • Default avatar
    Jan Walters
    VP of RA/QA

    Ms. Walters has over 20 years' experience in worldwide regulatory affairs and quality assurance in the medical device industry. Prior to joining GlySure she was V.P. QA/RA for Pfizer/Biomedical Sensors and worked directly with US, European, Canadian and Japanese regulatory agencies. Ms. Walters has a Masters degree in History from Oxford Brookes University and is a member of the Institute for Quality Assurance.


  • Default avatar

Previous Investors

  • Default avatar
    Amadeus Capital Partners, Delta Partners
    Default avatar
    Chester Investments, Morningside Ventures